Health Condition 1: C01- Malignant neoplasm of base of tongue Health Condition 2: C140- Malignant neoplasm of pharynx, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Are consecutive i.e. unselected undergoing either unilateral or bilateral tonsillectomy, tongue base mucosectomy, random biopsies, or guided biopsies for suspected HNSCCUP between 1st January 2015 and 31st December 2021 A minimum of 50 cases are required for centre participation All HNC sites will be included e.g. oral, oropharyngeal, laryngopharyngeal and nasopharyngeal Have unilateral or bilateral involved neck nodes Have a minimum of 2-year follow up or less if the patient has died. Have a diagnosis of squamous cell carcinoma on FNA or core biopsy or neck node biopsy or neck dissection Must have cross sectional imaging, either CT, MRI, PET-CT or combination having a PET-CT is not mandatory
Exclusion criteria
Exclusion criteria: Have distant metastatic disease on presentation Are less than 18 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a.In HNSCCUP non nasopharyngeal with unilateral neck disease what is the incidence of the primary tumour being identified in the ipsilateral tongue base b.To assess outcomes recurrence free survival and overall survival in a long term follow up study c.To assess the difference in locoregional recurrence and overall survival in patients with T0N1 HNSCCUP between those undergoing surgery or radiotherapy alone and those undergoing dual modality treatmentTimepoint: 1.Compare outcomes of surgery, radiotherapy, and dual modality treatments, including survival and mortality. 2.Assess detection rates by geography, HPV p16 status, and prior tonsillectomy. 3.Provide 5 year survival and recurrence free data. | — |
Secondary
| Measure | Time frame |
|---|---|
| a.To determine if the rate of tongue base primary detection varies dependent on patients having had prior tonsillectomy b) In HNSCCUP with unilateral neck disease, what is the incidence of the primary tumour in the ipsilateral tonsil, contralateral tonsil, or contralateral tongue base c) In HNSCCUP with bilateral neck disease what is the incidence of the primary tumour in the ipsilateral tonsil, contralateral tonsil, ipsilateral tongue base or contralateral tongue base d) To describe the incidence of HNSCCUP by p16 and HPV status and geography e) To determine the effect of treatment on outcomes specifically overall survival and 30-day mortality f) Determine the rate of primary site diagnosis from targeted and untargeted biopsiesTimepoint: overall survival and 30-day mortality | — |
Countries
Australia, India, Portugal, Singapore, Spain, United Kingdom, United States of America
Contacts
Public ContactDr Shivakumar Thiagarajan
Tata Memorial Hospital
Outcome results
None listed